ES2602078T3 - Composiciones y métodos para mejorar el potencial terapéutico de las células madre - Google Patents

Composiciones y métodos para mejorar el potencial terapéutico de las células madre Download PDF

Info

Publication number
ES2602078T3
ES2602078T3 ES13159548.0T ES13159548T ES2602078T3 ES 2602078 T3 ES2602078 T3 ES 2602078T3 ES 13159548 T ES13159548 T ES 13159548T ES 2602078 T3 ES2602078 T3 ES 2602078T3
Authority
ES
Spain
Prior art keywords
disease
cells
stem cells
msc
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13159548.0T
Other languages
English (en)
Spanish (es)
Inventor
Christian Van Den Bos
Barbara Reinisch
Claudia Rosenbaum
Judith Schenk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Cologne GmbH
Original Assignee
Lonza Cologne GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Cologne GmbH filed Critical Lonza Cologne GmbH
Application granted granted Critical
Publication of ES2602078T3 publication Critical patent/ES2602078T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
ES13159548.0T 2013-03-15 2013-03-15 Composiciones y métodos para mejorar el potencial terapéutico de las células madre Active ES2602078T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13159548.0A EP2777703B1 (en) 2013-03-15 2013-03-15 Compositions and methods for enhancing the therapeutic potential of stem cells

Publications (1)

Publication Number Publication Date
ES2602078T3 true ES2602078T3 (es) 2017-02-17

Family

ID=47900872

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13159548.0T Active ES2602078T3 (es) 2013-03-15 2013-03-15 Composiciones y métodos para mejorar el potencial terapéutico de las células madre

Country Status (10)

Country Link
US (4) US20160030482A1 (enExample)
EP (1) EP2777703B1 (enExample)
JP (1) JP6399410B2 (enExample)
KR (1) KR102203925B1 (enExample)
CN (1) CN105050597A (enExample)
AU (1) AU2014229502B2 (enExample)
BR (1) BR112015022565A2 (enExample)
CA (1) CA2905650C (enExample)
ES (1) ES2602078T3 (enExample)
WO (1) WO2014140930A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111405898B (zh) * 2018-01-29 2022-09-13 中国科学院动物研究所 一种破坏细胞机械稳态以及促进组织器官的再生修复的方法及其应用
HU231285B1 (hu) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
CN108728410B (zh) * 2018-06-19 2020-04-21 中国医学科学院阜外医院 基于药物预处理的间充质干细胞来源外泌体的制备方法
JP7230409B2 (ja) * 2018-10-02 2023-03-01 カシオ計算機株式会社 判定装置、判定方法及び判定プログラム
KR102932345B1 (ko) 2019-03-08 2026-02-27 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 식물 세포에서 니트로게나제 폴리펩티드의 발현

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011176A2 (en) 2006-07-21 2008-01-24 Northwestern University Myosin light chain kinase inhibitor compounds, compositions and related methods of use
CN101125146B (zh) * 2007-07-02 2011-05-04 中国药科大学 一种防治炎症相关心脑血管疾病的药物靶标及其抑制剂
AU2009208391A1 (en) * 2008-01-31 2009-08-06 Monash University Methods of treating thromboembolic disorders
EP2398897B1 (en) 2009-02-20 2017-06-28 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
AU2010236632A1 (en) * 2009-04-13 2011-09-15 The Regents Of The University Of California Methods and compositions for stem cell cultures
CN103201377A (zh) 2010-11-09 2013-07-10 隆萨科隆有限公司 控制细胞与基质结合的方法
CN102940631B (zh) * 2012-11-02 2015-04-15 清华大学 Blebbistatin在促进干细胞存活和维持干细胞干性中的应用

Also Published As

Publication number Publication date
JP6399410B2 (ja) 2018-10-03
US20200147142A1 (en) 2020-05-14
WO2014140930A2 (en) 2014-09-18
EP2777703A1 (en) 2014-09-17
AU2014229502B2 (en) 2019-03-14
CA2905650C (en) 2022-08-23
KR102203925B1 (ko) 2021-01-19
US20240316111A1 (en) 2024-09-26
US20160030482A1 (en) 2016-02-04
AU2014229502A9 (en) 2016-06-16
WO2014140930A9 (en) 2016-01-14
JP2016510808A (ja) 2016-04-11
CA2905650A1 (en) 2014-09-18
CN105050597A (zh) 2015-11-11
EP2777703B1 (en) 2016-09-14
BR112015022565A2 (pt) 2017-07-18
WO2014140930A3 (en) 2014-12-24
AU2014229502A1 (en) 2015-09-24
KR20150131324A (ko) 2015-11-24
US20180055888A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
US20240316111A1 (en) Compositions and methods for enhancing the therapeutic potential of stem cells
JP5968442B2 (ja) 心筋梗塞の修復再生を誘導する多能性幹細胞
ES2511791T3 (es) Células madre mesenquimales positivas para ABCB5 como moduladoras de inmunidad
Werber Amniotic tissues for the treatment of chronic plantar fasciosis and Achilles tendinosis
JP5340941B2 (ja) 血液、特に末梢血から成体幹細胞を増殖させるための方法及び医療分野におけるその利用
ES2673861T3 (es) Método novedoso para tratar el daño a la médula espinal utilizando el fragmento de hmgb1
JP2013513657A (ja) 新規ペプチドおよびその用途
AU2016328156B2 (en) Use of trientine to deliver copper to ischemic tissue
CN110724203B (zh) 一种促进tfeb核转位的短肽及基于其的线性短肽和其减轻脑缺血损伤的应用
JP2010504083A5 (enExample)
Radtke et al. Palifermin (Kepivance™) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support
Yim et al. Clinical study of cultured epithelial autografts in liquid suspension in severe burn patients
CN104862281A (zh) 表达bFGF和PDGF-BB的重组载体修饰的间充质干细胞及其制备方法和用途
JP7672636B2 (ja) 間葉系幹細胞の動員活性を有するペプチド
Wen et al. Revisiting the unobtrusive role of exogenous stem cells beyond neural circuits replacement in spinal cord injury repair
JP2021155335A (ja) 変形性関節症の処置および／または予防方法
CN106459902B (zh) 组织再生促进剂
WO2017066605A1 (en) Sequential application of macrophages for wound healing
Franco et al. Healing the Broken Hearts: A Glimpse on Next Generation Therapeutics
WO2024048652A1 (ja) 骨および／または軟骨再生用の組成物、骨および／または軟骨の疾患の処置および／または予防用の組成物
Werber Clinical Study Amniotic Tissues for the Treatment of Chronic Plantar Fasciosis and Achilles Tendinosis